# A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

> **NCT05519475** · PHASE2 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 120 (estimated)

## Conditions studied

- Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

## Interventions

- **DRUG:** ALN-HSD
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05519475
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-09
- **Primary completion:** 2028-04-27
- **Final completion:** 2028-12-07
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05519475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05519475, "A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05519475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*